Jiaxing Wang obtained his BS and MS degrees from Peking University Health Science Center (Beijing, China) before joining Dr Li’s lab at the University of Tennessee Health Science Center (UTHSC), Memphis, TN, USA in 2019. His current research focuses on evaluating new generations of tubulin inhibitors developed in Dr Li’s lab.

Dr Duane D. Miller received his Ph.D. degree in Medicinal Chemistry in 1969 from the University of Washington. He began his academic career at The Ohio State University and moved in 1992 to join the University to Tennessee College of Pharmacy (UTCoP). He retired in 2015 and is currently Professor Emeritus at UTHSC. His interests in drug design and the synthesis of new drug molecules continue, with a focus on tubulin inhibitors and drugs that act on the androgen receptor. His drugs for the treatment of prostate and breast cancers are currently in clinical trials.

Dr Wei Li obtained his BS degree in chemistry from the University of Science and Technology of China in 1992, and PhD degree from Columbia University in 1999. He has been working at the UTHSC College of Pharmacy since 1999. At present, he is a UTHSC Distinguished Professor, Director of UTCoP Drug Discovery Center, and the Faculty Director of the UTCoP Shared Instrument Facility. His research interest is in small molecule drug discovery and he currently has one drug in Phase 2 clinical trials. He is also the Founder and CSO of SEAK Therapeutics LLC, a UTHSC spin-off startup company.

© 2021 Elsevier Ltd. All rights reserved.